Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 9, 2024Deleted JournalOpen Access

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

HUHiroshi UreshinoHiroshima UniversityYUYasunori UedaKurashiki Central HospitalSFShin FujisawaYokohama City University Medical Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ureshino et al. (2024) studied this question.

synapsesocial.com/papers/68e7a413b6db64358770c13dhttps://doi.org/10.1016/j.bneo.2024.100001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Innate or Adaptive Immunity? The Example of Natural Killer Cells2011 · 2,827 citations
  2. 2The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity2010 · 91 citations
  3. 3Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics2012 · 19,341 citations
  4. 4KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation2017 · 143 citations
  5. 5Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study2017 · 295 citations